QUiCKR provides rapid quantification of genetic modifications, AAV titer, and structural variants essential for cell and gene therapy development. Their platform delivers results in minutes, significantly accelerating R&D and process development timelines compared to traditional NGS methods. This technology reduces hands-on time and operational costs associated with analyzing genome integrity and editing outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Cell and gene therapy development is slowed by the time-consuming process of quantifying genetic modifications. Traditional methods lack the throughput and speed required for rapid iteration and optimization.
Solution
QUiCKR Bio offers a platform for the instant quantification of genetic modifications using iCRISPR kinetic rates. This technology enables researchers to accelerate their cell and gene therapy development cycles by providing rapid feedback on the efficiency of CRISPR-based editing. The platform's automation-friendly, high-throughput format and pre-plated reagents streamline workflows, significantly reducing the time required for genomic analysis. By providing faster and more efficient quantification, QUiCKR Bio empowers researchers to iterate more quickly and accelerate their research.
Target Audience
The primary target audience includes researchers and scientists in cell and gene therapy development, particularly those utilizing CRISPR-based technologies for genome editing.
Features
- Quantification of genetic modifications using iCRISPR kinetic rates
- Automation-friendly design for seamless integration with robotic systems
- High-throughput format enabling parallel analysis of multiple samples
- Pre-plated reagents to minimize manual steps and reduce variability
- Streamlined workflow for faster turnaround times in genomic analysis